Evusheld, which is tixagevimab and cilgavimab, has proven effective against omicron’s early variants and subvariants, but in late June, the FDA recommended repeated dosing every six months as subvariant BA.5 quickly dominated cases.
Now, “there is a potential risk of treatment failure due to the development of viral variants that are resistant to tixagevimab and cilgavimab,” according to the FDA.
The regulator said it still recommends the treatment but adds that physicians “should consider the prevalence of SARS-CoV-2 variants in their area […] when considering prophylactic treatment options.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
